Literature DB >> 16631444

Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.

Carlo M Barbagallo1, Manfredi Rizzo, Davide Noto, Arian Frasheri, Vincenzo Pernice, Antonio Rubino, Daniele Pieri, Vito Pinto, Angelo B Cefalù, Carla Giordano, Alberto Notarbartolo, Maurizio R Averna.   

Abstract

Triglycerides (TGs) are vehicled by multiple particles with different abilities to promote atherosclerosis. Among plasma TG-rich lipoproteins (TRLs), subspecies may or may not contain apolipoprotein E (apoE) molecules: in this study, we evaluated the relative contribution of apoE-rich and apoE-poor TRLs to coronary atherosclerosis. We selected a group of males with premature coronary artery disease (CAD) without any of the classical nonlipid risk factors and/or high plasma lipid levels and evaluated the plasma concentration of TRL subspecies in comparison with healthy controls. Patients with CAD and controls had total cholesterol and TG levels within the normal range (despite slightly, even if significantly, higher TG levels in patients with CAD) and low-density lipoprotein cholesterol levels near optimal values. Nevertheless, patients with CAD had significantly lower high-density lipoprotein cholesterol, smaller low-density lipoprotein peak particle size, and a reduced HDL2b subfraction than controls. In addition, we observed higher concentrations of total TRL in patients with CAD together with a selective increase in apoE-rich particles. All these data were confirmed after correction for TG levels. We also investigated which parameters were associated with the spread of coronary atherosclerosis. Subjects with a single-vessel disease had selectively lower levels of apoE-rich fractions than patients with a multivessel disease. This was confirmed by multivariate analysis. Patients with a premature CAD free of nonlipid conventional risk factors, despite not having elevated lipid levels, show several lipoprotein abnormalities. Besides known atherogenic alterations, the accumulation of apoE-rich TRL subfractions may represent an additive factor that can potentially promote and initiate the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631444     DOI: 10.1016/j.metabol.2006.01.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.

Authors:  Amar A Sethi; Maureen Sampson; Russell Warnick; Nehemias Muniz; Boris Vaisman; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Alan T Remaley
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

2.  High serum apolipoprotein E determines hypertriglyceridemic dyslipidemias, coronary disease and apoA-I dysfunctionality.

Authors:  Altan Onat; Günay Can; Ender Ornek; Erkan Ayhan; Nihan Erginel-Ünaltuna; Sani N Murat
Journal:  Lipids       Date:  2012-10-25       Impact factor: 1.880

3.  Apolipoprotein E gene polymorphism and renal function are associated with apolipoprotein E concentration in patients with chronic kidney disease.

Authors:  Monika Czaplińska; Agnieszka Ćwiklińska; Monika Sakowicz-Burkiewicz; Ewa Wieczorek; Agnieszka Kuchta; Robert Kowalski; Barbara Kortas-Stempak; Alicja Dębska-Ślizień; Maciej Jankowski; Ewa Król
Journal:  Lipids Health Dis       Date:  2019-03-09       Impact factor: 3.876

4.  Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study.

Authors:  Sameer Fatani; Lucy C Pickavance; Claire J Sadler; Joanne A Harrold; Roslyn Cassidy; John Ph Wilding; Ebrahim K Naderali
Journal:  Nutr Metab (Lond)       Date:  2007-06-14       Impact factor: 4.169

5.  Interaction between VLDL and phosphatidylcholine liposomes generates new γ-LpE-like particles.

Authors:  Agnieszka Ćwiklińska; Barbara Kortas-Stempak; Anna Gliwińska; Anastasis Pacanis; Agnieszka Kuchta; Małgorzata Wróblewska
Journal:  Lipids       Date:  2014-02       Impact factor: 1.880

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.